Cambridge Heart to Exhibit at Sudden Cardiac Arrest Association 2009 Annual Meeting October 9th-11th.

The Event is Being Held in Conjunction with the Sudden Cardiac Arrest Awareness Month

TEWKSBURY, Mass. -- Cambridge Heart, Inc. (OTCBB-CAMH) will participate in the Sudden Cardiac Arrest Association's 2nd Annual Meeting and Medical Education Conference in Chicago, Illinois October 9th through the 11th, to showcase their Microvolt T-Wave Alternans(TM) (MTWA) technology designed to identify patients at risk for Sudden Cardiac Arrest (SCA). The exhibit will feature the HearTwave([R]) II, Cambridge Heart's flagship diagnostic system capable of performing both stress and MTWA testing.

The Sudden Cardiac Arrest Association (SCAA) is the largest advocacy organization in the U.S. exclusively dedicated to SCA. The 2009 Annual Meeting brings together survivors, patients, physicians, nurses, emergency professionals, and other community advocates working to broaden public awareness, improve emergency response, and increase access to preventive medical care - all with the goal of saving lives from sudden cardiac arrest.

"Our annual meeting coincides with Sudden Cardiac Arrest Awareness Month and SCAA values the support of Cambridge Heart as we work to raise public understanding about cardiac arrest risk factors and treatment options," said Chris Chiames, Executive Director of SCAA.

"SCA is the leading cause of death in the United States and can affect anyone," said Ali Haghighi-Mood, Cambridge Heart President and CEO. Our support of this important organization will help to increase awareness of the dangers of SCA and to educate on the importance of prediction and prevention."

Cambridge Heart manufactures the HearTwave([R]) II which incorporates its patented MTWA technology into a state-of-the-art stress system. MTWA is a tool that can be used to help identify and manage SCA risk for many patients including those with myocardial infarction (MI), heart failure, cardiomyopathy or syncope. Additional information on the product and the benefits of MTWA testing are available at www.CambridgeHeart.com

About Cambridge Heart, Inc.

Cambridge Heart develops and commercializes non-invasive diagnostic tests for cardiac disease, with a focus on identifying those at risk for sudden cardiac arrest (SCA). The Company's products incorporate proprietary Microvolt T-Wave Alternans[TM] measurement technologies, including the patented Analytic Spectral Method([R]) and ultrasensitive disposable electrode sensors. The Company's MTWA test, originally based on research conducted at the Massachusetts Institute of Technology, is reimbursed by Medicare under its National Coverage Policy.

Cambridge Heart, founded in 1990, is based in Tewksbury, MA. It is traded on the Over-The-Counter Bulletin Board (OTCBB) under the symbol CAMH.OB.

http://www.cambridgeheart.com.

Statements contained in this press release are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. In some cases, we use words such as "believes", "expects", "anticipates", "plans", "estimates", "could", and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements. Factors that may cause or contribute to such differences include failure to achieve broad market acceptance of the Company's MTWA technology, failure to raise new capital resources necessary to support our operations and to develop or enhance our technology, failure to initiate and conduct successfully new clinical trials and studies involving our technology, failure of our sales and marketing organization to market our products effectively, inability to hire and retain qualified clinical applications specialists in the Company's target markets, failure of our sales and marketing organization to market our products effectively, inability to hire and retain qualified clinical applications specialists in the Company's target markets, failure to obtain or maintain adequate levels of first-party reimbursement for use of the Company's MTWA test, customer delays in making final buying decisions, decreased demand for the Company's products, adverse results in future clinical studies of our technology, failure to obtain or maintain patent protection for our technology and other factors identified in our most recent Annual Report on Form 10-K under "Risk Factors", which is on file with the SEC and available at www.EDGAR.com. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so except as may be legally necessary, even if our estimates should change.